VORICONAZOLE-MEDIS voriconazole 50mg tablet blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

voriconazole, Quantity: 50 mg

Disponível em:

Medis Pharma Pty Ltd

DCI (Denominação Comum Internacional):

Voriconazole

Forma farmacêutica:

Tablet, film coated

Composição:

Excipient Ingredients: lactose monohydrate; magnesium stearate; povidone; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; triacetin; macrogol 3350

Via de administração:

Oral

Unidades em pacote:

56, 10, 2, 30, 28, 50, 14, 20, 100

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

VORICONAZOLE-MEDIS is indicated for treatment of the following fungal infections:,Invasive aspergillosis.,Serious Candida infections (including C. krusei), including oesophageal and systemic Candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,Serious fungal infections caused by Scedosporium spp and Fusarium spp.,Other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,Prophylaxis in patients who are at high risk of developing invasive fungal infections. The indication is based on studies including patients undergoing haematopoietic stem cell transplantation. This brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets.

Resumo do produto:

Visual Identification: white, round biconvex tablets, debossed 'VC50' on one side and plain on the reverse; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius

Status de autorização:

Licence status A

Data de autorização:

2015-02-02